Patents by Inventor Shannon BRUSE

Shannon BRUSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
    Publication number: 20240175031
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Application
    Filed: June 14, 2022
    Publication date: May 30, 2024
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS
    Publication number: 20230407299
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.
    Type: Application
    Filed: November 22, 2021
    Publication date: December 21, 2023
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David JAKUBOSKY, Sarah E. KLEINSTEIN, John VEKICH
  • Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1
    Publication number: 20230374145
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Application
    Filed: June 7, 2023
    Publication date: November 23, 2023
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
    Publication number: 20230357774
    Abstract: Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
    Type: Application
    Filed: September 28, 2021
    Publication date: November 9, 2023
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David LEWIS, David ROZEMA
  • PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230248752
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Application
    Filed: April 18, 2023
    Publication date: August 10, 2023
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
    Patent number: 11708415
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 25, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • Prodrugs of ALOX-15 inhibitors and methods of using the same
    Patent number: 11666588
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 6, 2023
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
    Publication number: 20230074280
    Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (lfTSLP).
    Type: Application
    Filed: August 23, 2022
    Publication date: March 9, 2023
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David Lewis, David ROZEMA
  • OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES
    Publication number: 20220340907
    Abstract: Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
    Type: Application
    Filed: May 4, 2022
    Publication date: October 27, 2022
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
    Patent number: 11452738
    Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 27, 2022
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
    Patent number: 11377658
    Abstract: Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: July 5, 2022
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
    Publication number: 20220056444
    Abstract: Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs) for therapeutic use, additionally, methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
    Type: Application
    Filed: December 3, 2019
    Publication date: February 24, 2022
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220047612
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Application
    Filed: August 5, 2021
    Publication date: February 17, 2022
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
    Publication number: 20220040220
    Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
    Type: Application
    Filed: January 3, 2020
    Publication date: February 10, 2022
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES
    Publication number: 20220002731
    Abstract: Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
    Publication number: 20210361693
    Abstract: Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs), antisense oligonucleotides, and small molecule inhibitors for therapeutic use. Additionally provided are methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 25, 2021
    Inventors: Shannon BRUSE, Brian CAJES, Omri GOTTESMAN, David ROZEMA, David LEWIS
  • Prodrugs of ALOX-15 inhibitors and methods of using the same
    Patent number: 11116778
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: September 14, 2021
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
    Publication number: 20210163950
    Abstract: Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
    Type: Application
    Filed: January 22, 2021
    Publication date: June 3, 2021
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David LEWIS, David ROZEMA
  • Treatment of angiopoietin like 7 (ANGPTL7) related diseases
    Patent number: 10941404
    Abstract: Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 9, 2021
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Paul Buske, Brian Cajes, David Lewis, David Rozema
  • PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20210030772
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Application
    Filed: January 14, 2020
    Publication date: February 4, 2021
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA